Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 150 | 41% |
| 2020 | 3 | 195 | 44% |
| 2021 | 1 | 217 |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Utah; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 35 | 2,932+9.5%/yr | +9.5%/yr | 0.8 | 78% | 6,310 in 2030+14%/yr |
| Arizona | 23 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 70 | 6,327+1.2%/yr | +1.2%/yr | 27.53.0× | 82% | 7,570 in 2030+3%/yr |
| Spinal cord & DRG stimulation |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
| ≈ 370 |
| – |
| 2026 est. | ≈ 410 | – |
| 48% |
| 2022 | 2 | 241 | 51% |
| 2023 | 1 | 276 | 54% |
| 2024 | 1 | 290 | 57% |
| 2025 from claims | – | 374 303–440 | 59% |
| 2026 forecast | – | 407 319–511 | 60% |
| 2027 forecast | – | 443 328–585 | 61% |
| 2028 forecast | – | 481 341–665 | 62% |
| 2029 forecast | – | 523 356–750 | 62% |
| 2030 forecast | – | 568 372–844 | 63% |
In 2025, 40% hospital outpatient, 51% surgery center, 9% office. The share outside the hospital has moved +35 pts since 2020, so more of this market is decided in surgery centers and offices each year.
| 1,632+19%/yr |
| +19%/yr |
| 2.0 |
| 90% |
| 3,070 in 2030+11%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.7 | 55% | 1,090 in 2030+11%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.0 | 55% | 1,080 in 2030+13%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.8 | 20% | 790 in 2030+12%/yr |
| Oregon | 4 | 325+4.4%/yr | +4.4%/yr | 0.7 | 91% | 1,740 in 2030+32%/yr |
| Nevada | 2 | 316−0.6%/yr | −0.6%/yr | 1.0 | 71% | 550 in 2030+9.6%/yr |
| 9 |
| 400+6.6%/yr |
| +6.6%/yr |
| 1.73.0× |
| 75% |
| 450 in 2030+2.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 35% of company spending on these surgeons in 2025, −19 pts on 2024.
In 2025, 9 companies reported engagement with Utah’s surgeons worth $54K in consulting, speaking, meals and travel tied to these products, about $54K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.